Last reviewed 2026-05-22 · How we verify

DEPREOTIDE

Phase 2 active Recombinant protein ✓ Verified May 2026

DEPREOTIDE is a depreotide drug. It is currently in Phase 2 development.

Depreotide works by binding to a specific target, although its exact mechanism of action is unknown.

Depreotide is a protein modality. It has been studied in clinical trials for various conditions, including knee osteoarthritis, shoulder pain, and hemiplegia, in combination with platelet-rich plasma treatment or hyaluronic acid treatment.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DEPREOTIDE
Drug class	depreotide
Modality	Recombinant protein
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of depreotide like a key that fits into a lock. When it binds to its target, it can help to turn off or reduce the activity of certain processes in the body. This can help to treat conditions where these processes are overactive or problematic.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DEPREOTIDE CI brief — competitive landscape report
DEPREOTIDE updates RSS · CI watch RSS

Frequently asked questions about DEPREOTIDE

What is DEPREOTIDE?

DEPREOTIDE is a depreotide drug.

How does DEPREOTIDE work?

Depreotide works by binding to a specific target, although its exact mechanism of action is unknown.

What drug class is DEPREOTIDE in?

DEPREOTIDE belongs to the depreotide class. See all depreotide drugs at /class/depreotide.

What development phase is DEPREOTIDE in?

DEPREOTIDE is in Phase 2.

Drug class: All depreotide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing